Jessie Wang, Meiling Zheng, Chunjuan Huang, Xuesong Huang, Yanrui Song, Wubin Qian, Likun Zhang, Jie Cai, Sheng Guo, Henry Q. X. Li, Davy X. Ouyang
The activation of Bruton's tyrosine kinase (BTK) is considered as a major oncogenic driver for various B cell-derived lymphoid cancers. Ibrutinib (a BTK inhibitor), has been approved for a range of malignancies, and has also shown encouraging efficacy in the ABC subtype of DLBCL.
Clinically relevant DLBCL models are now needed for further preclinical testing of ibrutinib and other BTK inhibitors. To meet this need, CrownBio has established a series of patient-derived xenograft (PDX) models, recapitulating the diverse genotypes of de novo DLBCL patients including MYD88L265P/CD79BY197N double mutants, a MYD88L265P single mutant model, and a variety of wild type PDX.
To complement these models, we have also established a cohort of EBV-transformed B lymphoma PDX, which share the similar histopathology as de novo DLBCL, but have distinct molecular pathology signatures and different pathogenesis.